tcr-therapeutics
(2)
T-Cypher Bio
T-Cypher Bio is an Oxford, UK biotechnology company building a pipeline of TCR (T cell receptor) therapeutics for solid tumours and immune-mediated diseases. Spun out of Orbit Discovery in 2021 on technology licensed from the University of Oxford, it pairs a high-throughput, functional bead-display platform with immunopeptidomics, AI and bioinformatics to deconvolute vast T cell repertoires, find disease-specific targets, and identify potent, target-specific TCRs.
Scott Peterson
Scott Peterson is the Chief Business Officer of T-Cypher Bio, an Oxford-based biotech building next-generation TCR therapeutics for solid tumors and autoimmune disease. A Harvard-trained PhD who started his career at the lab bench as a medicinal chemist at Merck, he crossed over to the deal side and spent two decades shaping pipelines and partnerships at Intarcia, Spero, and Dewpoint Therapeutics before taking the commercial helm at T-Cypher. He is the rare dealmaker who can read both a term sheet and a reaction mechanism.